June 17, 2020
3 min watch
Save
VIDEO: Investigational antibody-drug conjugate shows promise in breast cancer
In this video, Jame Abraham, MD, director of breast oncology at Cleveland Clinic, spoke about the phase 1 study of the investigational antibody-drug conjugate SGN-LIV1A (Seattle Genetics) for metastatic breast cancer, presented at ASCO20Virtual Scientific Program.
“We are excited about the potential of this drug, though this is an early phase of the trial,” Abraham told Healio. “This is a dose-escalation study ... where we’re trying to find the optimal dose, safety and then effect profile from this work.”
Abraham said he looks forward to moving on to a phase 2 study to investigate the drug’s efficacy once the optimal dose is determined.
Published by:
Sources/Disclosures
Collapse
Disclosures:
Abraham reports no relevant financial disclosures.
Read more from Discoveries in Breast Cancer
View allAugust 05, 2022
3 min watch
Save
August 05, 2022
4 min watch
Save
July 18, 2022
5 min watch
Save
July 01, 2022
7 min watch
Save
June 28, 2022
3 min watch
Save
June 27, 2022
2 min watch
Save
June 21, 2022
3 min watch
Save
June 21, 2022
3 min watch
Save
July 21, 2021
2 min read
Save
Read more about